Breaking News FDA Cleared Game-Changing Freestyle Libre 3 Reader

Press Release on April 14, 2023

Freestyle Libre 3 is one of the most innovative and high-tech continuous glucose monitoring (CGM) systems. It has earned significant popularity for its high accuracy in measuring your blood glucose levels. It comes with a compact sensor that the users wear on their skin.

The glucose level detected by the sensor is transmitted to your smartphone or a wireless connection and displayed before you.

Many users were waiting for Freestyle Libre 3 Reader to avoid compatibility and connectivity problems with their smartphones. They also wanted to cut off an extra step of installing a mobile App.

Here is the good news for the users who were waiting for Freestyle Libre 3 reader. Abbott has announced that the U.S. Food and Drug Administration (FDA) has cleared a reader for its Freestyle Libre® 3 integrated continuous glucose monitoring (CGM) system.

After having the FDA’s clearance of an individual reader, Abbott is striving to get the Freestyle Libre 3 system added to Medicare’s list of covered systems as soon as possible.

The Freestyle Libre 3 reader is a compact, portable apparatus that exhibits immediate blood glucose measurements directly from a diminutive sensor attached to the posterior side of an individual’s upper arm. This device offers a simple and convenient method for individuals with diabetes to manage their condition by viewing their glucose readings on a prominent, well-illuminated screen.

Moreover, users of the Freestyle Libre 3 system have the choice to employ smartphone applications. The reader operates with a rechargeable lithium-ion battery, which is a commonplace energy source in numerous other electronic gadgets such as mobile phones.

Reference : Abbott News Room